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Abstract
Objectives: To examine the usefulness of the Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis (ALS)
Screen (ECAS) as a cognitive screening tool for the detection of behavioral variant frontotemporal dementia (bvFTD).
A secondary aim was to determine whether people with FTD combined with ALS (ALS-FTD) exhibit a similar ECAS
profile to that of people with bvFTD alone. Methods: Patients with ALS-FTD and bvFTD and healthy controls were
recruited. Participants were administered the ECAS, which comprises tests of language, verbal fluency, executive func-
tions, memory, and visual-spatial functions. They also carried out analogous, full-length cognitive tests that examine
naming, spelling, sentence completion, and social cognition skills. Results: The study cohort comprised 20 ALS-FTD
patients, 23 with bvFTD, and 30 controls. Highly significant group differences were elicited for all cognitive domains,
reflecting poorer performance in patients compared to controls. No significant differences in overall test scores were
found between ALS-FTD and bvFTD patients, although ALS-FTD patients showed a higher frequency of impairment
on verbal fluency. Correlative analyses revealed inter-relationships in patients (but not controls) between scores in differ-
ent domains, most marked in bvFTD. There were strong correlations between performance on ECAS subtests and
analogous cognitive tasks. Conclusion: The ECAS is a sensitive and valuable tool for the assessment of FTD. Executive,
language and behavioral breakdown may, however, compromise performance in other cognitive domains, reducing the
specificity of the ‘frontotemporal’ cognitive profile. Subtle differences observed between ALS-FTD and bvFTD raise
questions regarding the precise relationship between bvFTD with and without ALS.
Keywords: Motor neurone disease, frontotemporal dementia, cognition
Introduction
The Edinburgh Cognitive and Behavioral ALS
Screen (ECAS) (1) is a well-established screening
instrument for detecting cognitive impairments in
amyotrophic lateral sclerosis (ALS). It has been
translated into multiple languages (2–6) and vali-
dated in different populations (2,7–10), showing
impressive levels of sensitivity and specificity. Its
relative brevity means that the ECAS is appropri-
ate for use with patients who are unable to tolerate
lengthy cognitive assessments.
The ECAS is founded on the recognized link
between ALS and frontotemporal dementia
(FTD). ALS patients show deficits in the same
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domains of cognitive function most affected in
FTD (11): language, verbal fluency, executive
functions, and social cognition. A key strength of
the ECAS is its distinction between those “ALS-
specific” domains, mediated by frontotemporal
lobe functioning and most likely to be affected in
ALS, and other cognitive domains not thought to
be specific to ALS: memory and visuospatial func-
tions. Performance profiles offer the potential to
distinguish ALS cognitive impairment from that of
other neurodegenerative disorders such as
Alzheimer’s disease (AD) (6) and to have more
widespread implications for differential diagnosis
of neurodegenerative disease, according to the like-
lihood of frontotemporal symptomatology (12).
ECAS studies have hitherto focused primarily
on ALS patients who exhibit cognitive impairment
(ci), behavioral impairment (bi) or both (cbi),
according to current definitions of frontotemporal
spectrum disorder (11), but who do not meet full
criteria for behavioral variant FTD (bvFTD) (13).
There are relatively few data pertaining specifically
to people with established bvFTD, who by defin-
ition, have more severe cognitive/behavioral
impairment than the majority of people with ALS.
The primary purpose of the present study was to
examine the usefulness of the ECAS as a cognitive
screening tool for the detection of bvFTD. It explores
the relationship between ALS-specific and ALS non-
specific cognitive domains because of the potential
for interactions between performance in different cog-
nitive domains, particularly executive functions and
memory. A subsidiary aim was to determine whether
people with FTD combined with ALS (ALS-FTD)
exhibit an ECAS profile identical to or different from
that of people with bvFTD alone.
The study forms part of a broader investigation
of cognitive and behavioral changes in ALS-FTD
and bvFTD, supported by the Motor Neurone
Disease Association.
Method
Participants
The study cohort comprised patients clinically
diagnosed with bvFTD or ALS-FTD, recruited
from specialist cognitive and motor neurone dis-
ease clinics within the NorthWest of England.
Patients were included if they fulfilled contempor-
ary diagnostic criteria for bvFTD (13) and were in
the mild-to-moderate stage of the disease, as meas-
ured by the Clinical Dementia Rating scale modi-
fied for use with FTD patients (14). ALS-FTD
patients also fulfilled the El Escorial criteria for
ALS (15). ALS-FTD patients were excluded if
they fell into the ‘very severe’ range of disability
(score < 12), as measured by the ALS Functional
Rating Scale revised (16), or if they required
mechanical respiratory support. Healthy controls
were recruited via a local research register of vol-
unteers and through the national Join Dementia
Research initiative. Participants were excluded if
they had a history of head injury, alcohol or sub-
stance abuse, symptoms, and signs of cerebrovas-
cular disease or clinically significant anxiety or
depression. All participants were native English
speakers. The study was approved by the North
West Ethics committee (REC reference 14/NW/
1185). Participants (together with their carer in
the case of patients) provided informed written
consent to participate and for the future publica-
tion of fully anonymized material pertaining
to them.
Cognitive assessment
The ECAS addresses five domains of function:
language, verbal fluency, executive skills, memory,
and visuospatial skills. It encompasses the follow-
ing subtasks: picture naming, comprehension,
spelling, generation of words beginning with S,
generation of four-letter words beginning with T,
digit reversal, the alternation between numbers
and letters, unconnected sentence completion,
social cognition (judgment of preference), immedi-
ate recall of the story, retention over the delay, rec-
ognition memory, dot counting, cube counting,
and number location. The test was administered
according to published guidelines (https://ecas.psy.
ed.ac.uk), with patients being offered the oppor-
tunity to choose between oral and written modes
of response to optimize accessibility for ALS
patients with reduced bulbar/limb function. For
verbal fluency, a verbal fluency index was calcu-
lated to adjust for motor deficits.
To enable direct comparison of performance
on ECAS language, executive and social cognition
tasks with that of standard full-length neuro-
psychological tests that assess the same cognitive
domains, the study also included the following
tests: Graded Naming test (17), a 30-item picture
naming test of graded difficulty; PALPA spelling
(18); the accuracy score from part B of the
Hayling sentence completion test (19) that taps
generation and response inhibition and a Judgment
of Preference from eye gaze test (20,21) that is a
marker of social cognition.
All patient assessments were conducted by the
same administrator (JAS) and control tests by JAS,
JCT, or JMH. Testers were trained in ECAS
administration and had years of experience in the
clinical assessment of patients with FTD.
Behavioral screen
The ECAS includes a behavioral screen, which
covers the core domains of behavioral change
specified in diagnostic criteria for bvFTD (13).
Since all patients, by definition, fulfilled behavioral
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criteria for bvFTD, the behavioral screen was not
evaluated as part of the current study.
Statistics
Statistical analyses were carried out using IBM SPSS
Statistics version 25. Group comparisons involved
chi-squared tests for categorical data, with Fisher’s
Exact test applied when cells had expected frequen-
cies below 5. Analysis of variance was used for inter-
val data and Kruskal–Wallis and Mann–Whitney U
tests for ECAS measures, for which data were not
normally distributed. Significance values shown in
tables are uncorrected. They survive Bonferroni cor-
rection for multiple comparisons except where stated
in the text. The effect size was calculated using the
formula r¼Zn as described by Rosenthal (22).
Control percentile scores were calculated to deter-
mine impaired performance in individual patients,
defined as lower than the 5th percentile of control
performance. Correlations between tests were carried
out using Spearman’s rho test. Significance levels are
uncorrected.
Results
Demographics
Forty-three patients fulfilled the criteria for the study
within the recruitment period, 23 with bvFTD, and
20 with ALS-FTD. Thirteen ALS-FTD patients had
some degree of bulbar involvement at the time of
testing. Thirty healthy controls were recruited via a
local research register of volunteers and through the
national Join Dementia Research initiative. There
was a preponderance of male patients in the patient
groups (Table 1). ALS-FTD patients were older
than controls, whereas bvFTD patients showed no
significant difference in age. bvFTD patients had
fewer years of education than controls, whereas years
of education did not differ significantly between the
ALS-FTD group and either the bvFTD or control
group.
Group comparison of ECAS domain and total scores
An examination of ECAS domain, ALS-specific,
ALS nonspecific, and total scores revealed highly
significant group differences for all cognitive
domains, based on Kruskal–Wallis tests (Table 2).
Post hoc Mann–Whitney U tests showed that these
differences lay exclusively between patients and
controls. The bvFTD and ALS-FTD groups each
performed more poorly than controls, with signifi-
cance levels at p< 0.001 for all domains. No dif-
ferences in scores between bvFTD and ALS-FTD
groups reached conventional levels of significance
of p< 0.05. The highly significant differences
between patient groups and controls (p<0.001)
remained when younger and more educated
Table 1. Demographics Characteristics.
Patients
Controls p-ValueALS-FTD bvFTD
Number 20 23 30
Gender, M:F 12:8 14:9 9:21 v2 ¼ 6.58 0.04
Age, mean (SD) 65 (8) 60 (7) 59 (8) F¼3.89 0.03^
Years of education, mean (SD) 13 (3) 12 (3) 14 (3) F¼3.86 0.03
Duration, mean years (SD) 3 (1) 5 (4) n/a t¼2.6 0.02
Dementia severity1 9.5 (2.8) 9.3 (2.8) n/a t¼0.26 0.80
^Differences lie between ALS-FTD and control (post-hoc Bonferroni test p¼0.03). Differences lie between bvFTD
and control (post-hoc Bonferroni test p¼0.02). Other comparisons non-significant.
1Modified Clinical Dementia Rating, mean number of boxes (14).
Table 2. Group comparisons of ECAS domains.
Patients
Controls Statistic Group analysisALS-FTD bvFTD
Median (range) Median (range) Median (range) Kruskall–Wallis p-Value
Language/28 21 (5–28) 20 (1–28) 28 (25–28) 35.3 <0.001a,b
Verbal fluency/24 3 (0–14) 8 (0–18) 20 (6–24) 42.8 <0.001a,b
Executive/48 19.5 (4–43) 23.5 (4–42) 40.5 (30–45) 32.9 <0.001a,b
Memory/24 7 (0–16) 10 (0–21) 18 (12–22) 34.5 <0.001a,b
Visuospatial/12 11 (3–12) 11 (0–12) 12 (11–12) 21.2 <0.001a,b
ALS total/100 45 (12–81) 55.5 (14–87) 89 (72–95) 40.0 <0.001a,b
Non-ALS total/36 19 (6–27) 16 (0–32) 30 (24–34) 36.7 <0.001a,b
ECAS total/136 65 (18–98) 78 (15–119) 118 (100–127) 40.3 <0.001a,b
Post-hoc Mann–Whitney test significant at p<0.001 between aALS-FTD and controls and bbvFTD and controls. No significant
differences between ALS-FTD and bvFTD were observed.
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controls were excluded so that the groups were
matched for age and education.
Not all patients were able to complete all tasks.
In the bvFTD group, patients’ behavioral/cognitive
disorder precluded assessment of verbal fluency in
one case and of executive function in three cases.
In the ALS-FTD group, six patients could not be
assessed on at least one domain because of a com-
bination of behavioral/cognitive and physical diffi-
culty: two for language, six for verbal fluency, four
for executive functions, three for memory, and
three for visuospatial function. In those patients,
the absence of data for one or more tasks pre-
cluded the calculation of a meaningful overall
domain score (although ‘impairment’ could be
inferred).
Patients’ total scores for ALS-specific and
ALS-nonspecific tasks were expressed as a propor-
tion of the maximum possible score (100 and 36,
respectively). A Wilcoxon test showed no differ-
ence in relative performance for these two broad
aspects of cognitive function in either patient
group: ALS-FTD z ¼ 0.63, p¼0.53; bvFTD z
¼ 0.52, p¼0.60.
Subdomain performance in FTD
Patients’ impaired performance in non-ALS spe-
cific, as well as ALS-specific domains, is notable.
It raises the question of whether there are particu-
lar subtests within each domain that are particu-
larly vulnerable to impairment. Performance on
individual subtests is shown in Table 3. In view of
the absence of significant domain differences
between ALS-FTD and bvFTD groups these
patient groups are considered together as a com-
posite FTD group for subdomain analyses and
compared to controls. Each subtest within the
domains of language, verbal fluency, and executive
functions elicited significant group differences,
most at p< 0.001 (Table 3). Following Bonferroni
correction for multiple comparisons (p<0.003)
differences on dot counting and number location
tests no longer reached statistical significance. The
largest effect size was elicited for verbal fluency,
immediate recall, and inhibitory sentence
completion.
Frequency of impairment
Table 4 shows the percentage of ALS-FTD and
bvFTD patients whose performance fell below the
5th percentile of control group scores, and on that
basis can be considered impaired. For verbal flu-
ency, one outlier control score was excluded in
order to normalize the distribution upon which
percentiles were calculated. Both ALS-FTD and
bvFTD groups showed a high frequency of impair-
ment in all cognitive domains. There was a higher
frequency of impairment in ALS-FTD than
bvFTD for verbal fluency (Fisher’s Exact (n¼ 43),
p¼ 0.04). Frequency of impairment in the two
patient groups (n¼43) did not differ significantly
for other domains: Language Fisher’s Exact,
p¼ 0.73, Executive Fisher’s Exact p¼0.25,
Memory v2(1, n¼43) ¼ 0.97, p¼0.32, visuo-
spatial skills v2 ¼ 0.05, p¼ 0.82 ALS-specific total
Fisher’s Exact, p¼0.42, ALS nonspecific v2 ¼
1.16, p¼ 0.28, Total ECAS Fisher’s
Exact p¼0.11.
In the bvFTD group, ALS-specific domain
impairment was slightly more common than for
ALS nonspecific domains (Fisher’s Exact test
(n¼ 23), p¼0.03). Differences in these domains
did not reach significance in the ALS-FTD group
(Fisher’s Exact test (n¼ 20), p¼0.63). Overall,
the ALS-specific domain showed high sensitivity in
detecting impairment: ALS-FTD 90%, bvFTD
Table 3. ECAS subtests: FTD patients (ALS-FTDþbvFTD) compared to controls.
Test
FTD Controls Mann–Whitney
p-Value Effect sizeMedian Range Median Range U z
ALS-specific
Naming/8 6 1–8 8 7–8 177.0 5.5 <0.001 0.65
Comprehension/8 8 0–8 8 8–8 375.0 4.0 <0.001 0.47
Spelling/12 8 0–12 12 10–12 199.5 5.0 <0.001 0.60
Fluency letter S/12 1 0–10 10 4–12 60.0 6.4 <0.001 0.78
Fluency letter T/12 0 0–10 10 4–12 73.0 6.3 <0.001 0.77
Reversed digits/12 4 0–8 8 4–10 151.5 5.5 <0.001 0.65
Alternation/12 6 0–12 12 5–12 222.0 4.7 <0.001 0.56
Sentence completion/12 4.5 0–11 11 4–12 127.0 5.7 <0.001 0.68
Social cognition/12 6 0–12 12 6–12 277.5 3.9 <0.001 0.47
ALS nonspecific
Immediate recall/10 2 0–7 7 4–10 105.0 6.1 <0.001 0.71
Retention over delay/10 3 0–10 9 4–10 316.0 3.6 <0.001 0.42
Delayed recognition/4 1 0–4 2 0–4 270.5 3.9 <0.001 0.47
Dot counting/4 4 0–4 4 3–4 437.5 2.9 0.004 0.34
Cube counting/4 3.5 0–4 4 3–4 315.0 4.2 <0.001 0.50
Number location/4 4 0–4 4 3–4 450.0 2.7 0.007 0.32
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78%, but low specificity in relation to ALS-non-
specific impairment: ALS-FTD 20%,
bvFTD 35%.
To enable direct comparison with studies of
ALS, the percentage of impaired patients, based
on originally published cutoffs (1) and revised age
and education-adjusted cutoffs (9) are also shown
in Table 4. The latter seemed particularly relevant
in view of differences in age and education
between patients and controls. Frequencies of
impairment according to these different criteria
yield a coherent pattern, with slightly more conser-
vative estimates of impairment typically elicited
when age and education adjusted norms are
applied.
Correlation between domains
Domain scores showed no significant inter-correla-
tions in the control group, possibly reflecting ceil-
ing level scores on some tasks. In the patient
groups, significant inter-correlations were appar-
ent, particularly marked in bvFTD (Table 5).
Inter-correlations in ALS-FTD were generally
non-significant, the notable exception being the
strong relationship between verbal fluency and
executive scores (rs(11) ¼ 0.75, p¼0.003). In
bvFTD, strong correlations between language and
memory performance were present for immediate
recall (rs(21) ¼ 0.74, p< 0.001), delayed recall
(rs((21) ¼ 0.69, p<0.001) and delayed recognition
(rs(21) ¼ 0.57, p¼0.005), whereas correlations
between executive performance and memory were
mainly driven by the immediate recall (rs(18) ¼
0.57, p¼0.008). Executive performance and
delayed recall showed a more modest association
(rs(18) ¼ 0.52, p¼ 0.02) and delayed recognition
no significant relationship (rs(18) ¼
0.29, p¼0.22).
ECAS scores in relation to standard neuropsychological
tests
There were strong correlations between patients’
performance on ECAS language and executive
tests and their corresponding full version neuro-
psychological test: ECAS naming and Graded
Naming (rs(39) ¼ 0.65, p<0.001); ECAS spelling
and PALPA spelling (rs(34) ¼ 0.86, p< 0.001;
ECAS sentence completion and Hayling test
(rs(29) ¼ 0.68, p<0.001); ECAS social cognition
and Judgment of Preference (rs(30) ¼ 0.64,
p< 0.001). The sensitivity of the task in detecting
impairment, based on control cutoff scores, was
broadly similar, albeit slightly higher for the full
test version: ECAS naming 56%, Graded naming
68%; ECAS spelling 61%, PALPA spelling 64%;
ECAS sentence completion 55%, Hayling test
76%; ECAS social cognition 47%, Judgment of
Preference 55%. Specificity was 100%, with the
exception of PALPA spelling (93%), ECAS sen-
tence completion (97%), and Judgment of
Preference (97%).
Discussion
The findings indicate that the ECAS is highly sen-
sitive to the cognitive impairment of people with
the behavioral form of FTD, both when this
occurs in the context of ALS and in isolation.
Unsurprisingly, the level and frequency of impair-
ment are substantially greater than typically
reported in studies of ALS.
The impairments demonstrated in language,
verbal fluency, and executive functions accord with
expectation and are in keeping with findings of
excellent sensitivity of the ECAS to these
Table 4. Percentage of patients showing impairment.
Criterion Below 5th percentile of control scores Using 2014 cutoffs (1) Using age and education adjusted cutoffs (9)
Domain ALS-FTD bvFTD ALS-FTD bvFTD ALS-FTD bvFTD
Language 80 74 85 78 65 61
Verbal fluency 95 70 100 70 95 78
Executive 90 74 90 74 80 70
Memory 75 61 80 78 60 61
Visuospatial 40 44 40 44 35 43
ALS-specific 90 78 95 87 85 70
ALS nonspecific 80 65 80 74 60 57
Total/136 100 83 100 91 85 74
Table 5. Inter-correlations between domains in ALS-FTD and
bvFTD (Spearman’s rho).
Verbal
fluency Executive Memory Visuo-spatial
ALS-FTD – – – –
Language 0.51 0.35 0.13 0.25
Verbal Fluency – 0.75 0.19 0.48
Executive – – 0.06 0.39
Memory – – – 0.11
bvFTD – – – –
Language 0.74  0.77 0.78 0.66
Fluency – 0.71 0.70 0.40
Executive – – 0.62 0.67
Memory – – – 0.43
p<0.001; p<0.01; p<0.05.
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ALS-specific impairments (7). It is notable, how-
ever, that impairments were demonstrated with
high frequency also for ALS nonspecific cognitive
domains, driven particularly by poor memory test
performance. Indeed, immediate recall elicited the
highest effect size in the data set after verbal flu-
ency, substantially higher than that for social cog-
nition. Such findings suggest that whereas the
ECAS is sensitive to the type of cognitive dysfunc-
tion associated with frontotemporal spectrum dis-
order some diagnostic specificity may be lost when
the test is applied to patients whose disorder is suf-
ficiently severe to meet criteria for bvFTD since
patients perform poorly across all or most tasks.
Early consensus criteria for frontotemporal
dementia (23) identified “severe amnesia” and
“visuospatial disorder” as exclusion criteria for
FTD. Similarly, revised criteria (13) refer to
“relative sparing of episodic memory” and “relative
sparing of visuospatial skills” in bvFTD. Why then
should the boundaries between ALS-specific and
ALS nonspecific domains be so blurred? The clue
lies in the qualifying terms used in published con-
sensus statements: “no severe amnesia” and
“relative sparing of memory”. It is to be expected
that the performance will not be entirely normal.
bvFTD patients with severe frontal executive dis-
order inevitably perform poorly on open-ended
memory tests by virtue of executive demands on
attention and use of strategy. It is instructive that
executive scores correlated specifically with imme-
diate recall, suggesting a failure of registration of
information secondary to executive factors. It is
notable too that memory performance in bvFTD
was strongly related to language performance. The
ECAS memory task takes the form of a verbal nar-
rative in which the discrete elements to be recalled,
which include people’s names and numbers, are
essentially unrelated. The specific characteristics of
the task might render performance particularly vul-
nerable to both executive and language
impairments.
The findings reinforce earlier reports that test
scores alone may mask different reasons for test
failure: bvFTD patients make more frequent con-
fabulatory and misconstruction responses in story
recall compared to AD patients (24), suggesting a
greater contribution of executive breakdown.
Distinct neural substrates have also been demon-
strated. One imaging study (25) found that the
frontal and anterior temporal lobes underpinned
episodic memory in bvFTD, but a more wide-
spread network in AD. Another study (26) showed
a correlation between memory performance and
frontal lobe atrophy in bvFTD but both medial
temporal and frontal lobe atrophy in AD. Memory
performance in bvFTD may, moreover, be task-
dependent: bvFTD patients show impaired imme-
diate recall (24,27) but less rapid loss than AD
patients over a delay. Explicit memory in bvFTD
is reported to be poorer than implicit memory but
may benefit from retrieval cues (28). Arguably, the
open-ended ECAS story recall task may not be the
optimal memory measure in the differential diag-
nosis of FTD.
A smaller proportion of ALS-FTD and bvFTD
patients showed impairment in visuospatial com-
pared to memory tests. Nevertheless, here too
there was a correlation in bvFTD between visuo-
spatial and both language and executive test per-
formance, complementing previous findings that
executive impairments may impact secondarily per-
formance on visuospatial tasks (24): bvFTD
patients made organizational but not spatial errors
in the drawing.
Correlations between domain scores were
much less apparent in ALS-FTD than bvFTD.
The ALS-FTD group was smaller at the outset
and further diminished by ‘missing’ data due to
patients’ inability to comply with tasks. Thus, the
ALS-FTD data has reduced the power to elicit
statistical effects. Nevertheless, this is unlikely to
provide a sufficient explanation. The correlation
between verbal fluency and executive performance
in ALS-FTD (0.75) was as strong as those correla-
tions found in bvFTD. By contrast, no association
was found with language scores. The disparities
raise the possibility that different factors may
underpin performance breakdown in bvFTD and
ALS-FTD. The disproportionately high frequency
of impairment in verbal fluency in ALS-FTD com-
pared to bvFTD is instructive given that verbal flu-
ency deficits are the most frequently reported
cognitive deficit in ALS (29). Moreover, the asso-
ciation of verbal fluency performance with deficits
in executive, rather than primary language, skills
accords with earlier findings in ALS (30).
Behavioral changes, present in all patients,
together with physical limitations in ALS-FTD
compound the challenges of cognitive assessment
in FTD. Notwithstanding the obstacles, there were
strong correspondences between performance on
naming, spelling, sentence completion, and social
cognition subtests of the ECAS and longer,
‘standard’ versions of those same tasks, providing
evidence of convergent validity and complementing
previous findings (7,9).
A limitation of the present study was the
imprecise matching of groups. Nevertheless, com-
parisons of patient and control performance
yielded similar frequencies of impairment as com-
parisons with published ECAS norms (1), slightly
more conservative estimates of frequency arising
when compared to age and education adjusted
norms (9). Moreover, comparisons using only a
sub-cohort of the control group matched for age
and education yielded similar results. The rela-
tively small sample size of the two patient groups
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and, in particular, ‘missing’ data, due to patients’
inability to engage with the task, may have reduced
the power to detect potential differences between
bvFTD and ALS-FTD. It is notable, for example,
that ALS-FTD patients achieved a numerically
lower median verbal fluency score than bvFTD
patients: 3 compared to 8, yet the group difference
was non-significant. By contrast, the analysis of
the frequency of impairment, involving a larger
number of patients because it included those
unable to comply for behavioral/cognitive reasons,
yielded a significant group difference. The study
necessitated the use of nonparametric statistical
techniques because of the skewed distribution of
data. More powerful parametric methods may
have been possible with a larger sample. Studies
involving larger patient cohorts are warranted. The
study cohort represents a prevalent sample and so
caution is needed in assuming that it is fully repre-
sentative of an incident population. Selection bias,
arising from a volunteer cohort of patients, would,
however, more likely lead to an underestimate
rather than overestimate of cognitive impairment,
suggesting that the ECAS findings are likely to be
robust.
The findings in bvFTD and ALS-FTD add to
the body of knowledge about the ECAS in neuro-
degenerative disease. The high frequency of
impairment is similar to that reported in progres-
sive supranuclear palsy and contrasts with the
much lower frequency of impairment (30%) found
in Parkinson’s disease (12). It is, moreover, higher
than typically found in studies of ALS. In a com-
parative study of ALS and AD (6) 50% of the
ALS group showed impaired performance, but
only 21% impairment on ALS nonspecific tasks.
The latter proved most sensitive in differentiating
ALS and AD. The implication is that only when
executive and language breakdown becomes
severe, as in FTD, does it impact secondarily on
visuospatial and memory test performance.
Conclusions
The ECAS is highly sensitive to the cognitive
changes in FTD and as such can be considered a
valuable screening tool. Nevertheless, changes in
behavior, language, and executive function, inher-
ent in FTD, can have a secondary impact on test
performance in other cognitive domains, thereby
obscuring putative dissociations and complicating
diagnostic differentiation. Thus, the ECAS, when
performance is impaired, should be considered a
prelude to more extensive neuropsychological
assessment that includes a qualitative examination
of performance, with a focus on the analysis of
errors as well as test scores. Normal ECAS per-
formance, in patients with ALS, may obviate the
immediate need for full psychometric testing,
although clinical monitoring at intervals and
rechecking of behavior with relatives is recom-
mended. Subtle differences observed in this study
between ALS-FTD and bvFTD underscore the
importance of a more extensive evaluation of
behavior and cognition in these two patient
groups.
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